Trials / Unknown
UnknownNCT05905380
Covid-19 Convalescent Plasma and Monoclonal Antibodies Treatment of Immunocompromised Patients
Analysis of the Efficacy and Tolerance of Covid-19 Convalescent Plasma and Monoclonal Antibodies in the Treatment of SARS-Cov2 Infections in Immunocompromised Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (estimated)
- Sponsor
- University Hospital, Strasbourg, France · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Data on the use of convalescent plasma in the treatment of covid-19 are scarce: the results of randomized studies involving mainly immunocompetent patients are disappointing, while case series or retrospective data on more selected patients , in particular immunocompromised patients suggest a benefit in these patients whose clinical manifestation seems essentially related to the uncontrolled infection and not the cytokine storm.
Conditions
Timeline
- Start date
- 2023-03-02
- Primary completion
- 2024-01-31
- Completion
- 2024-01-31
- First posted
- 2023-06-15
- Last updated
- 2023-06-18
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05905380. Inclusion in this directory is not an endorsement.